Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Ruriko Tanaka; Shinya Kimura; Eishi Ashihara; Mariko Yoshimura; Naoto Takahashi; Hisashi Wakita; Kuniaki Itoh; Kaichi Nishiwaki; Kenshi Suzuki; Rina Nagao; Hisayuki Yao; Yoshihiro Hayashi; Sakiko Satake; Hideyo Hirai; Ken ichi Sawada; Oliver G. Ottmann; Junia V. Melo; Taira Maekawa

doi:10.1016/j.canlet.2011.08.009

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

Ruriko Tanaka, Shinya Kimura, Eishi Ashihara, Mariko Yoshimura, Naoto Takahashi, Hisashi Wakita, Kuniaki Itoh, Kaichi Nishiwaki, Kenshi Suzuki, Rina Nagao, Hisayuki Yao, Yoshihiro Hayashi, Sakiko Satake, Hideyo Hirai, Ken ichi Sawada, Oliver G. Ottmann, Junia V. Melo, Taira Maekawa

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

12 被引用数 (Scopus)

抄録

ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL ⁺ leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

本文言語	英語
ページ（範囲）	228-234
ページ数	7
ジャーナル	Cancer Letters
巻	312
号	2
DOI	https://doi.org/10.1016/j.canlet.2011.08.009
出版ステータス	出版済み - 12月 22 2011
外部発表	はい

!!!All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.canlet.2011.08.009

他のファイルとリンク

引用スタイル

Tanaka, R., Kimura, S., Ashihara, E., Yoshimura, M., Takahashi, N., Wakita, H., Itoh, K., Nishiwaki, K., Suzuki, K., Nagao, R., Yao, H., Hayashi, Y., Satake, S., Hirai, H., Sawada, K. I., Ottmann, O. G., Melo, J. V., & Maekawa, T. (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters, 312(2), 228-234. https://doi.org/10.1016/j.canlet.2011.08.009

Tanaka, R, Kimura, S, Ashihara, E, Yoshimura, M, Takahashi, N, Wakita, H, Itoh, K, Nishiwaki, K, Suzuki, K, Nagao, R, Yao, H, Hayashi, Y, Satake, S, Hirai, H, Sawada, KI, Ottmann, OG, Melo, JV & Maekawa, T 2011, 'Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients', Cancer Letters, vol. 312, no. 2, pp. 228-234. https://doi.org/10.1016/j.canlet.2011.08.009

@article{ab9a3eee65a9488fbe293289c8c454a0,

title = "Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients",

abstract = "ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.",

author = "Ruriko Tanaka and Shinya Kimura and Eishi Ashihara and Mariko Yoshimura and Naoto Takahashi and Hisashi Wakita and Kuniaki Itoh and Kaichi Nishiwaki and Kenshi Suzuki and Rina Nagao and Hisayuki Yao and Yoshihiro Hayashi and Sakiko Satake and Hideyo Hirai and Sawada, {Ken ichi} and Ottmann, {Oliver G.} and Melo, {Junia V.} and Taira Maekawa",

note = "Funding Information: We thank Naoko Hashimoto and Mikiko Katakami for technical support. We would also like to thank Jun Kuroki, Atsushi Kitabayashi, Hisako Iso, Hideyoshi Noji and Hideo Kimura, and all the various clinical centres participating in this study. This work was partly supported by Grant-in-Aids for Scientific Research and for the Japan Society for the Promotion of Science (JSPS) fellows, by the Global COE Program “Centre for Frontier Medicine” from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by Management Expenses Grants from the Government to the National Cancer Centre of Japan. ",

year = "2011",

month = dec,

day = "22",

doi = "10.1016/j.canlet.2011.08.009",

language = "English",

volume = "312",

pages = "228--234",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

AU - Tanaka, Ruriko

AU - Kimura, Shinya

AU - Ashihara, Eishi

AU - Yoshimura, Mariko

AU - Takahashi, Naoto

AU - Wakita, Hisashi

AU - Itoh, Kuniaki

AU - Nishiwaki, Kaichi

AU - Suzuki, Kenshi

AU - Nagao, Rina

AU - Yao, Hisayuki

AU - Hayashi, Yoshihiro

AU - Satake, Sakiko

AU - Hirai, Hideyo

AU - Sawada, Ken ichi

AU - Ottmann, Oliver G.

AU - Melo, Junia V.

AU - Maekawa, Taira

N1 - Funding Information: We thank Naoko Hashimoto and Mikiko Katakami for technical support. We would also like to thank Jun Kuroki, Atsushi Kitabayashi, Hisako Iso, Hideyoshi Noji and Hideo Kimura, and all the various clinical centres participating in this study. This work was partly supported by Grant-in-Aids for Scientific Research and for the Japan Society for the Promotion of Science (JSPS) fellows, by the Global COE Program “Centre for Frontier Medicine” from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by Management Expenses Grants from the Government to the National Cancer Centre of Japan.

PY - 2011/12/22

Y1 - 2011/12/22

N2 - ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

AB - ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR-ABL + leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=80053987395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053987395&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.08.009

DO - 10.1016/j.canlet.2011.08.009

M3 - Article

C2 - 21890264

AN - SCOPUS:80053987395

VL - 312

SP - 228

EP - 234

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

抄録

!!!All Science Journal Classification (ASJC) codes

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル